BGNE — Beigene Share Price
Last trade - 00:00- $15.32bn
- $12.01bn
- CNY7.59bn
- 18
- 12
- 41
- 13
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.74 | ||
| Price to Tang. Book | 2.79 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 18.28 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -30.13% | ||
| Return on Equity | -69.11% | ||
| Operating Margin | -226.83% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | n/a | 1,310.03 | 2,954 | 2,120.2 | 7,588.96 | 10,025.14 | 13,748.9 | 79.6% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BeiGene, Ltd. (BeiGene) is a global biotechnology company. The Company is focused on discovering, developing, manufacturing, and commercializing medicines to improve treatment outcomes and expand access for patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers, tislelizumab; an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers, and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company also has other products in its clinical stage, including BGB-283, BGB-3245, BGB-11417, BGB-A445, BGB-A425, BGB-15025, BGB-A333, BGB-A1217, and BGB-10188. The Company operates offices in 30 countries on five continents, namely the United States, China, Europe, and Australia.
Directors
- John Oyler CHM (53)
- Xiaobin Wu PRE (59)
- Xiaodong Wang CFD (57)
- Julia Wang CFO (50)
- Jane Huang OTH (48)
- Hing Ling Chau SEC
- Anthony Hooper NED (66)
- Timothy Chen NID (64)
- Han Dugan NID (65)
- Donald Glazer NID (76)
- Michael Goller NID (46)
- Ranjeev Krishana NID (47)
- Thomas Malley NID (52)
- Alessandro Riva NID (61)
- Corazon Sanders NID (64)
- Qingqing Yi NID (49)
- Last Annual
- December 31st, 2021
- Last Interim
- March 31st, 2022
- Incorporated
- October 28th, 2010
- Public Since
- February 3rd, 2016
- No. of Shareholders
- 83,751
- No. of Employees
- 8,033
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 1,450,235,805
- Address
- Ke Xue Yuan Lu 30 Hao,Zhong Guan Cun, GRAND CAYMAN, KY1-1108
- Web
- http://www.beigene.cn/
- Phone
- +1 3459494123
- Auditors
- Ernst & Young LLP
Upcoming Events for BGNE
Similar to BGNE
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
ACADIA Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 19:02 UTC, shares in Beigene are trading at $137.32. This share price information is delayed by 15 minutes.
Shares in Beigene last closed at $137.32 and the price had moved by -60.1% over the past 365 days. In terms of relative price strength the Beigene share price has underperformed the S&P500 Index by -57.5% over the past year.
The overall consensus recommendation for Beigene is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Beigene does not currently pay a dividend.
Beigene does not currently pay a dividend.
Beigene does not currently pay a dividend.
To buy shares in Beigene you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $137.32, shares in Beigene had a market capitalisation of $15.32bn.
Here are the trading details for Beigene:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: BGNE
Based on an overall assessment of its quality, value and momentum Beigene is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Beigene is $333.35. That is 142.76% above the last closing price of $137.32.
Analysts covering Beigene currently have a consensus Earnings Per Share (EPS) forecast of -CNY92.97 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Beigene. Over the past six months, its share price has underperformed the S&P500 Index by -54.78%.
As of the last closing price of $137.32, shares in Beigene were trading -48.59% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Beigene PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $137.32.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Beigene's management team is headed by:
- John Oyler - CHM
- Xiaobin Wu - PRE
- Xiaodong Wang - CFD
- Julia Wang - CFO
- Jane Huang - OTH
- Hing Ling Chau - SEC
- Anthony Hooper - NED
- Timothy Chen - NID
- Han Dugan - NID
- Donald Glazer - NID
- Michael Goller - NID
- Ranjeev Krishana - NID
- Thomas Malley - NID
- Alessandro Riva - NID
- Corazon Sanders - NID
- Qingqing Yi - NID